openPR Logo
Press release

Histone Deacetylase Inhibitors Market Key Players : Celgene, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals, Novartis, Merck & Co., and Pfizer.

10-26-2018 10:23 AM CET | Health & Medicine

Press release from: Allied Market Research

The Histone deactylase inhibitor (HDAC) is a molecule that consists of different compounds that form a group of anticancer agents. The parent epigenetic market of HDAC is expected to grow at a CAGR of around 30% worldwide from 2013 to 2020. The factors driving this market are increase in cancer incidences, ongoing research and development for the treatment of cancer, other diseases, and the need to improve the effectiveness of new therapies. The major limitation of this market is reimbursement and uncertainty issues. The opportunities for this market are increase in collaborations and huge investments in manufacturing which will ensure significant growth.

Key market players of this market are, Celgene, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals, Novartis, Merck & Co., and Pfizer.

Get Sample PDF Brochure : https://www.alliedmarketresearch.com/request-toc-and-sample/61

KEY BENEFITS:

• The report provides Market attractiveness analysis for the most attractive geographical region worldwide, and considers factors responsible for rapid growth in the regions.
• Various economic factors which are significant in determining market trend, buying decisions and market attractiveness are been analyzed for market estimation and forecasting
• The report evaluates the key factors of drivers, restraints and opportunities enabling strategic decision making with perceptive to identify potential market.
• The study also discusses various environmental and regulatory factors critical for the market growth.
• The analysis will support stakeholders such as manufacturers and distributors in identifying and capturing markets with high potential.

KEY MARKET SEGMENTS

GLOBAL MARKET BY, CLASS

• Class I HDACs
• Class II HDACs
• Class III HDACs

GLOBAL MARKET BY, APPLICATIONS

• Cancer
• Central Nervous System Disorders
• Other Diseases

GLOBAL MARKET BY, GEOGRAPHY

• Europe
• North America
• Asia - Pacific
• RoW

KEY AUDIENCES:

• Health care centers
• Research facilities
• Academic institutes
• Pharmaceutical companies

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Histone Deacetylase Inhibitors Market Key Players : Celgene, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals, Novartis, Merck & Co., and Pfizer. here

News-ID: 1330978 • Views:

More Releases from Allied Market Research

Fashion Events Market Size Worth USD $61.5 Billion by 2032, Growth Rate (CAGR) of 5.3%
Fashion Events Market Size Worth USD $61.5 Billion by 2032, Growth Rate (CAGR) o …
According to a new report published by Allied Market Research, titled, "Fashion Events Market Size, Share, Competitive Landscape and Trend Analysis Report by Type, by Revenue Source, by Organizer: Global Opportunity Analysis and Industry Forecast, 2023-2032" The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. The global fashion events market size was
Sustainable Tourism Market Size Worth USD $11.4 Trillion by 2032, Growth Rate (CAGR) of 14% From 2023-2032
Sustainable Tourism Market Size Worth USD $11.4 Trillion by 2032, Growth Rate (C …
According to a new report published by Allied Market Research, titled, "Sustainable Tourism Market" The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. In 2023, the coastal tourism segment occupied the largest market share as it is one of the most popular types of sustainable tourism locations in the world due to
Pearl Jewelry Market Size to Hit US$ 42 Billion by 2031, Growing Almost 13.2% CAGR From 2022-2031
Pearl Jewelry Market Size to Hit US$ 42 Billion by 2031, Growing Almost 13.2% CA …
According to a new report published by Allied Market Research, titled, "Pearl Jewelry Market by Type, by Material, by Pearl Nature, by Pearl Source, by Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022-2031" The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. The global pearl jewelry market was valued at $12.8
Lottery Market Projected to Acquire $430.4 Billion by 2031, Strong Growth at 3.8% CAGR From 2021-2031
Lottery Market Projected to Acquire $430.4 Billion by 2031, Strong Growth at 3.8 …
According to a new report published by Allied Market Research, titled, "Lottery Market by Type, by Application: Global Opportunity Analysis and Industry Forecast, 2021-2031". The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. The global lottery market was valued at $300.6 billion in 2021, and is projected to reach $430.4 billion by

All 5 Releases


More Releases for HDAC

Histone Deacetylase (HDAC) Inhibitors Market 2022 | Detailed Report
The Histone Deacetylase (HDAC) Inhibitors research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the
HDAC Inhibitors Market - Increasing R&D activities for cancer is expected to boo …
Overview HDAC inhibitors are a kind of anti-cancer drug that works by causing cell cycle arrest, apoptosis, and death in cancer cells through non-epigenetic or epigenetic control. HDAC inhibitors (HDACi) are potential medicines that have already demonstrated promise in oncological applications such as cancer detection, treatment, and prognostic. Vorinostat (Merck & Co. Inc.) is a new medication that is used to treat epidermal T cell lymphoma as it progresses, relapses, or
HDAC Inhibitors Market - Trends and Opportunities 2017 - 2025
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,